Followers | 20 |
Posts | 5392 |
Boards Moderated | 0 |
Alias Born | 01/04/2012 |
![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Saturday, August 03, 2013 8:18:28 AM
Much of the so called grasping, has also been sort of a warning to management to think twice, if they think they can get away with it. I, as many of us just won't disappear into the night. I mean Simes even called me a couple of times to to get me to vote for the merger. Knowing I would post it. They were reading the BPAX board's comments. I know he was using me, but he also knew my intentions, he knows that as a police officer I was building a case, not in an official capacity, yet. I still am. I believe (now, this may be grasping) that I won't have to use it.
Most times, when investors get defrauded, police have to build a case from scratch. It is time consuming trying to put all the pieces of the puzzle together in a chronological order. Not all cases get investigated due to sheer volume. They must prioritize cases on the likelihood of success. The better the chances of solving the case the more likely they are to bump up the investigation. I am trying to increase their chances of success and raise the profile of our case should we ever have to resort to it. Management of Big Pharma is not worried about litigation and eventually settling is part of doing business. On the other hand, the possibility of serving time in prison is not part of doing business for them.
The fact the CV benefits were never clearly stated in public nor expanded upon, especially when the company was facing an R/S due to share price listing requirements, as an investigator, is a big red flag and leads me to believe there is something else at play. The patent was filed in July 2011 claiming a 71% reduction in CV events over placebo. This patent claims it was an accidental discovery
[0025] The invention is predicated, in part, upon the unexpected findings from a US-based, multi-center, randomized, placebo-controlled Phase 3 clinical trial, where the administration of a precise amount of testosterone in a transdermal formulation to postmenopausal women at high risk for cardiovascular events reduced the number of cardiovascular events compared to the expected number of cardiovascular events for an untreated postmenopausal woman. The findings indicate an unanticipated lower than expected cardiovascular event rate in postmenopausal woman using testosterone for the treatment of cardiovascular events.
Why hold back such important information and let your name become mud? Simes was nominated as one of the Worst CEOs. His reputation has taken a beating yet he sat on the above info. It just doesn't add up.
For the time being, I am giving Przybyl the benefit of the doubt and will allow him to execute his strategy, on the possibility that there is a master plan in play, beyond the simple acquisition of Biosante's cash. And, I will continue to dig to find the motive behind what we have experienced over the last two years.
Recent ANIP News
- ANI Pharmaceuticals Announces the FDA Approval and Launch of Naproxen Delayed-Release Tablets, USP • GlobeNewswire Inc. • 07/02/2024 11:00:00 AM
- ANI Pharmaceuticals’ CEO Nikhil Lalwani Named EY Entrepreneur Of The Year® 2024 New Jersey Award Winner • GlobeNewswire Inc. • 06/25/2024 11:00:02 AM
- ANI Pharmaceuticals to Further Expand Rare Disease Business through Acquisition of Alimera Sciences • GlobeNewswire Inc. • 06/24/2024 10:50:44 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/18/2024 08:37:33 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/17/2024 09:05:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 09:23:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/11/2024 08:51:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 10:21:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 11:34:13 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 11:59:24 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/04/2024 10:08:03 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/04/2024 08:35:27 PM
- ANI Pharmaceuticals to Present at the 2024 Jefferies Global Healthcare Conference • GlobeNewswire Inc. • 05/29/2024 08:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/24/2024 12:03:53 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/24/2024 12:02:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2024 11:58:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2024 11:54:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2024 11:45:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 08:06:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 10:14:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2024 09:21:53 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/20/2024 08:57:32 PM
- ANI Pharmaceuticals Announces the Launch of Kionex® Suspension • GlobeNewswire Inc. • 05/20/2024 10:50:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 10:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 10:01:01 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM